TABLE 2.

MICs of different pump substrates for AcrB mutants of E. coli 3-AG100a

MutationMIC (μg/ml)
OxacillinDoxoru-bicinNovobi-ocinClarithro-mycinErythro-mycinAzithro-mycinClin-damycinPyronin YLinezolidMino- cyclinEtBrLevo-floxacinCipro-floxacinHoechst 33342Propidium iodidePAβNChloram-phenicolTetra-cyclineNMPSpectino-mycinGenta-micin
F628F wild type (pseudomutation)>256>25651251251264256325124>25610.54>512>40084400328
acrB::rpsL-neo 0.524440.540.5160.125160.060.030.251285011
F136A6464646416
F178A32166412816640.5
F610A6412832166423220.251280.130.0625610021
F615A64643232
F617A128
Δ615-61764321281281
F628A1281286416811
  • a Gentamicin, spectinomycin, and NMP are not substrates of AcrB and were used as controls. For the mutants only the MICs that were ≥4-fold different from the wild-type MIC (F628F pseudomutant) are shown. The substrates and control substances are in order (from left to right) based on the differences in the MICs between the wild type (pseudomutant F628F) and the inactivation mutant (acrB::rpsL-neo).